Peptic ulcer disease

Current Opinion in Gastroenterology

Volumn 20, Issue 6, 2004, Pages 533-537

  Louw, Japie A ^a,c   Marks, I N ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c HOTEL DIEU HOSPITAL   (Canada)

Author keywords

Helicobacter pylori; Nonsteroidal antiinflammatory drugs; Peptic ulcer disease; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BENATOPRAZOLE; BENZIMIDAZOLE; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; LANSOPRAZOLE; LICOFELONE; NAPROXEN; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

BACTERIAL INFECTION; CANCER PREVENTION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; ENDOSCOPY; ERADICATION THERAPY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PH MEASUREMENT; REVIEW; RISK ASSESSMENT; STEADY STATE; STOMACH CANCER;

EID: 7444236482     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200411000-00005     Document Type: Review

References (26)

1. Hammer J, Eslick GD, Howell SC, et al.: Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004, 53:666-672.
2. Moayyedi P: Bringing science to the art of diagnosis. Gut 2004, 53:627-628.
3. Thompson ABR, Barkun AN, Armstrong D, et al.: The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003, 17:1481-1491.
4. Bramble MG, Svakovic Z, Hungin AP: Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy. Gut 2000, 46:464-467.
5. Panter SJ, O'Flanagan H, Bramble MG, et al.: Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not affect outcome. Aliment Pharmacol Ther 2004, 19:981-988.
6. Todd JA, Richards CJ, Dixon A, et al.: Gastric ulcer and malignancy - is there a need for follow-up endoscopy? Aliment Pharmacol Ther 2004, 19:989-991. Suggests that follow-up endoscopy to confirm gastric ulcer healing could be the exception rather than the rule. Based on the finding that more than 200 repeat upper endoscopies would have to be performed to detect a single unsuspected cancer, which may then not be curable.
7. Wong BC-Y, Lam SK, Wong WM, et al.: Helicobacter pylori eradication to prevent gastric cancer in a high risk region of China. A randomized controlled trial. JAMA 2004, 291:187-194. Addresses a pivotal question: does eradication of H. pylori protect against future development of gastric cancer? Unfortunately, the study will probably be viewed as inconclusive, it raises important questions in subanalysis.
8. Parsonnet J, Forman D: Helicobacter pylori infection and gastric cancer-for want of more outcomes. JAMA 2004, 291:244-245.
9. Gisbert JP, Khorrami S, Carbalho F, et al.: Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004, 19:617-629.
10. Gillen D, Wirz AA, McColl KEL: Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004, 126:980-988. Documents acid rebound phenomenon after cessation of omeprazole, after H. pylori has been eradicated.
11. Vaira D, Vakil N, Rugge M, et al.: Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 2003, 52:1543-1547.
12. Cremonini F, Di Caro S, Delgado-Aros S, et al.: Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003, 18:279-289.
13. Megraud F, Lamouliatte H: Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003, 17:1333-1343.
14. Galmiche JP, Bruley des Varennes S, Ducrotté P, et al.: Tenatoprazole, a novel proton pump inhibitor with prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004, 19:655-662.
15. Miner P, Katz PO, Chen Y, et al.: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003, 98:2616-2620.
16. Pantoflickova D, Dorta G, Ravic M, et al.: Acid inhibition on the first day of dosing: comparison of for proton pump inhibitors. Aliment Pharmacol Ther 2003, 17:1507-1514.
17. Lisse JR, Perlman M, Johansson G, et al.: Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis. Ann Intern Med 2003, 139:539-546.
18. Hawkey CJ, Laine L, Simon T, et al.: Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen or placebo: a multicentre, randomized, double blind study. Gut 2003, 52:820-826.
19. Nø'rgård B, Pedersen L, Johnssen SP, et al.: Cox-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004, 19:817-825.
20. MacDonald TM, Morant SV, Goldstein JL, et al.: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003, 52:1265-1270. Provides evidence that "safer" agents are prescribed to sicker patients, as would be expected. May go some way to explain the clinical observation of complications still found in patients taking COX-2-selective agents.
21. Dubois RW, Melmed GY, Henning JM, et al.: Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyco-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic antiinflammatory therapy. Aliment Pharmacol Ther 2004, 19:197-208.
22. CAPRIE Steering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
23. Ng FH, Wong SY, Chang CM, et al.: High incidence of clopidogrel- associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003, 18:443-449. Raises concern with regard to the use of clopidogrel in what would traditionally be viewed as higher risk patients. More work is required in this field.
24. Fiorucci S, Santucci L, Gresele P, et al.: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124:600-607. Potentially important new agents, reported in proof of concept phase.
25. Hawkey CJ, Jones JI, Atherton CT, et al.: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donor: proof of concept study in humans. Gut 2003, 52:1537-1542. See [24•].
26. Bias P, Buchner A, Klesser B, et al.: The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004, 99:611-618. See [24•].